Expression of the target receptor CD33 in CD34+/CD38-/CD123+ AML stem cells

Area of Science:

• Hematology
• Immunology
• Cancer Biology

Background:

• CD33 (Siglec-3) is a key target for antibody therapies in acute myeloid leukaemia (AML).
• In normal blood development, CD33 is expressed late, not on primitive stem cells.
• This study investigated CD33 expression on leukaemic stem cells in AML.

Purpose of the Study:

• To determine if leukaemic stem cells in AML patients express CD33.
• To evaluate the potential of CD33 as a target for AML treatment.

Main Methods:

• Utilized multicolour staining and cell sorting to isolate leukaemic progenitors (CD34+/CD38-/CD123+).
• Analyzed CD33 mRNA expression in purified leukaemic stem cells using RT-PCR.
• Confirmed AML stem cell populations via NOD/SCID mouse repopulation experiments.

Main Results:

• Leukaemic progenitors from CD33-positive AML patients expressed CD33.
• AML stem cells in CD33-positive AML reside within the CD33+ subpopulation.
• CD33 mRNA was detected in highly purified leukaemic stem cells from CD33+ AML patients.
• CD33 was absent on normal hematopoietic stem cells and leukaemic stem cells in CD33-negative AML.

Conclusions:

• Leukaemic stem cells in CD33-positive AML patients demonstrably express CD33.
• This supports the development of novel therapeutic strategies targeting CD33 in AML.